NICE says yes and no to Amgen's Xgeva
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, maintains that Amgen's Xgeva (denosumab) would not be cost-effective for preventing skeletal-related events in adults with bone metastases from prostate cancer on the National Health Service. However, according to today's final appraisal determination, it still looks set to recommend the drug for preventing SREs in other patients.